Prostate cancer is the development of cancer in a gland, the prostate, in the male's reproductive system. 30 million men in Europe are confronted with a diagnosis of prostate cancer in their lifetime and each year 75,000 men die from prostate cancer.
Prostate cancer incidence has doubled since 1995, surpassing both lung and colorectal cancer incidence with 22% of all newly diagnosed cancer cases in 2018 being diagnosed as prostate cancer. However, it is unclear to what extent the significant increase in prostate cancer incidence is driven by detection of latent disease due to the increase in PSA testing.
In 2018, prostate cancer incidence ranged from 63.6 of 100,000 inhabitants in Romania to 211.6 in Sweden, with the EU28+EFTA average at 151.2.
In 2018, prostate cancer mortality ranged from 50.9 of 100,000 inhabitants in Estonia to 18.9 in Luxembourg, with the EU28+EFTA average at 32.8.
In 2010-2014, prostate cancer 5-year survival rates ranged from 68.3% in Bulgaria and 94.3% in Lithuania.